Amersham: New study using Ettan DIGE technology reveals significant results

24-Mar-2004 - A new study published in Proteomics1 shows that two-dimensional difference gel electrophoresis (2-D DIGE) technology provided by Amersham Biosciences, the life sciences business of Amersham, reveals statistically significant differences in protein abundance between normal and colorectal cancer ...

Amersham Biosciences broadens range of cellular analysis solutions with Guava Technologies' Japan distribution deal

25-Feb-2004 - Amersham Biosciences, the life sciences business of Amersham, has signed an exclusive three-year distribution agreement covering the territory of Japan with Guava® Technologies, Inc for Guava Personal Cell Analysis (PCA) systems, reagents and software modules. By adding the Guava PCA systems to ...

Amersham and Bayer Diagnostics sign exclusive development and supply agreement for diagnostic sequencing

17-Feb-2004 - London, UK and Tarrytown, NY - Amersham and the Diagnostics Division of Bayer HealthCare LLC, a member of the Bayer Group ("Bayer"), announced they have entered into an exclusive worldwide agreement for joint development of assays and instrumentation in the field of human immunodeficiency virus ...

Amersham plc appoints Peter Loescher as Chief Operating Officer

17-Nov-2003 - Amersham plc announced the appointment of Peter Loescher to the role of Chief Operating Officer, effective 1 January 2004. Mr Loescher, 46, joined the company in December 2002 as President of Amersham Health and an Executive member of the Amersham plc Board. In this new role Mr Loescher will ...

Lilly Complements its Drug Discovery Research with Integrated Cellular Screening System from Amersham Biosciences

11-Nov-2003 - Amersham, a world leader in medical diagnostics and in life sciences, announces that Eli Lilly and Company has purchased an integrated suite of cellular screening technology and licenses to help in the identification of potential therapeutics in its drug discovery program. In addition to the ...

Amersham Biosciences and GeneBio expand alliance to develop next generation proteomics image analysis software

Agreement expands the strategic alliance between the two companies signed in January 2003 to develop and distribute novel proteomics analysis software, databases and training tools

23-Jul-2003 - Amersham Biosciences, the life sciences business of Amersham and Geneva Bioinformatics S.A. have signed an exclusive agreement to provide researchers with the next generation of 2-D gel image analysis tools for proteomics research. This collaboration between Amersham Biosciences and GeneBio will ...